Conversion Labs, Inc (CVLB)
| Market Cap | 347.79M |
| Revenue (ttm) | 28.34M |
| Net Income (ttm) | -30.61M |
| Shares Out | 14.67M |
| EPS (ttm) | -2.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $17.72 |
| Previous Close | $12.87 |
| Change ($) | 4.85 |
| Change (%) | 37.68% |
| Day's Open | 12.68 |
| Day's Range | 12.51 - 18.44 |
| Day's Volume | 2,759,199 |
| 52-Week Range | 5.99 - 18.44 |
NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc . (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, reported preliminary unaudited results for its fourth qua...
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed licensed personal care and wellness physician and ps...
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has been invited to present at H.C. Wainwright's BioConnect Confere...
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed digital marketing expert and industry thought-leader...
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc . (NASDAQ: CVLB), a direct-to-consumer telemedicine and wellness company, reported its annualized revenue run-rate reached a r...
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc . (NASDAQ: CVLB), a direct-to-consumer telemedicine and wellness company, has officially launched its new Veritas MD telehealt...
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, has received approval to uplist to the Nasdaq Capital ...
NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc . (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, has appointed expert Life Sciences attorney, Eric H. ...
Conversion Labs' (CVLB) CEO Justin Schreiber on Q3 2020 Results - Earnings Call Transcript
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB) (OTCQB: CVLBD), a direct-to-consumer telemedicine and wellness company, has appointed Roberto Simon to its board...
NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB) (OTCQB: CVLBD), a direct-to-consumer telemedicine and wellness company, will hold a conference call on Monday, N...
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc . (OTCQB: CVLB) (OTCQB: CVLBD), a direct-to-consumer telemedicine and wellness company, has closed on approximately $14.5 mill...
NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB) (OTCQB: CVLBD), a direct-to-consumer telemedicine and wellness company, has signed a licensing agreement with Re...
Dizzying triple-digit rate growth looks to be continuing for quite a while due to the introduction of a new platform. The company can add brands and products almost at will. The platform and m...
About CVLB
Conversion Labs operates as a direct response healthcare company that provides over the counter products and prescription medications to consumers worldwide. The company's products include Shapiro MD, a shampoo, conditioner, and leave-in-foamer for treating hair loss; iNR Wellness MD, a nutritional supplement for immune and gut support; RexMD for the treatment of cold sores, mental health, and various other medical conditions faced by men; SOSRx, a telemedicine brand that offers prescription medications and over-the-counter emergency preparatio... [Read more...]
| Industry Pharmaceutical Retailers | Founded 1994 |
| CEO Justin Schreiber | Employees 26 |
| Stock Exchange NASDAQ | Ticker Symbol CVLB |
Financial Performance
In 2019, CVLB's revenue was $12.47 million, an increase of 49.79% compared to the previous year's $8.32 million. Losses were -$3.14 million, 152.8% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for CVLB stock is "Strong Buy" and the 12-month stock price forecast is 15.00.